Evidence map›Paper›PMID 39170621›Full record

ArticleFrontiers in immunology2024

Viral escape mutations do not account for non-protection from SIVmac239 challenge in RhCMV/SIV vaccinated rhesus macaques.

Benjamin N Bimber, Justine Sunshine, G W McElfresh, Jason S Reed, Reese Pathak, Katherine B Bateman, Colette M Hughes, Roxanne M Gilbride, Julia C Ford, David Morrow and 4 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Benjamin N BimberOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Justine SunshineVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.
G W McElfreshOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Jason S ReedOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Reese PathakOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Katherine B BatemanOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Colette M HughesVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.
Roxanne M GilbrideVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.
Julia C FordVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.
David MorrowVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD, United States.
Jonah B SachaOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Scott G HansenOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Louis J PickerOregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Consortia for Innovative AIDS Research in Nonhuman PrimatesUM1AI124377 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., PICKER, LOUIS J. · 2016 to 2021
$53.0M
Project 3: Determination of the minimal MHC-E-restricted SIV epitope targeting required for RhCMV/SIV vaccine-mediated SIV replication arrest efficacyP01AI174856 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Louis J. Picker · 2022 to 2026
$29.9M
Virology and Immunology MonitoringP01AI094417 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J. · 2011 to 2016
$20.5M
Virology and Vector Production Core CU19AI128741 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI STREBLOW, DANIEL N · 2017 to 2021
$11.8M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS P01 AI094417NIAID NIH HHS P01 AI174856NIAID NIH HHS U19 AI128741NIAID NIH HHS UM1 AI124377NIH HHS P51 OD011092
6 · The paper itself

Abstract

Simian immunodeficiency virus (SIV) vaccines based upon 68-1 Rhesus Cytomegalovirus (RhCMV) vectors show remarkable protection against pathogenic SIVmac239 challenge. Across multiple independent rhesus macaque (RM) challenge studies, nearly 60% of vaccinated RM show early, complete arrest of SIVmac239 replication after effective challenge, whereas the remainder show progressive infection similar to controls. Here, we performed viral sequencing to determine whether the failure to control viral replication in non-protected RMs is associated with the acquisition of viral escape mutations. While low level viral mutations accumulated in all animals by 28 days-post-challenge, which is after the establishment of viral control in protected animals, the dominant circulating virus in virtually all unprotected RMs was nearly identical to the challenge stock, and there was no difference in mutation patterns between this cohort and unvaccinated controls. These data definitively demonstrate that viral mutation does not explain lack of viral control in RMs not protected by RhCMV/SIV vaccination. We further demonstrate that during chronic infection RhCMV/SIV vaccinated RMs do not acquire escape mutation in epitopes targeted by RhCMV/SIV, but instead display mutation in canonical MHC-Ia epitopes similar to unvaccinated RMs. This suggests that after the initial failure of viral control, unconventional T cell responses induced by 68-1 RhCMV/SIV vaccination do not exert strong selective pressure on systemically replicating SIV.

Indexed as

Macaca mulattaMutationSAIDS VaccinesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsCytomegalovirusImmune EvasionVaccinationVirus ReplicationSAIDS VaccinesCMV vaccine vectorHIV/SIVSIVviral escapeviral sequence analysis

Identifiers

PMID39170621
PMCPMC11336698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.